CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zura Bio plunges after skin disease drug fails mid-stage study

By Reuters News

** Shares of biotech firm Zura Bio ZURA.O plunge 68.2% to $1.30 premarket

** Co says experimental drug tibulizumab failed the main goal of a 247-patient study in hidradenitis suppurativa, a chronic disease that causes painful lumps under the skin

** Drug also missed key secondary goals, including measures of at least 50% and 75% reductions in skin lesions — ZURA

** Two doses reduced lesion counts by 56% and 58.1%, versus 52.5% for placebo after 16 weeks — ZURA

** Zura will discontinue the drug’s development for the skin disease but continue studies in two other inflammatory conditions

** As of last close, stock down ~22% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.